IMAGIN Medical

Investor Center

Corporate Profile

Imagin Medical, a surgical imaging company, is focusing on bladder cancer, the sixth most prevalent cancer in the U.S. and the third most common cancer in men. It is the most expensive form of cancer to treat over the lifetime of a patient because the cancer will return in more than 50% of cases. Approximately 600,000 people are living with that fear in the U.S. today. It is estimated that in 2021, 83,000 new cases of bladder cancer will be diagnosed, and more than 17,000 deaths will occur.*

*https://seer.cancer.gov/statfacts/html/urinb.html

Corporate Presentation

Investor Presentation - Q4 2021, Visualizing Cancer in a Different Light.

IMEXF, IME

Recent News

8 November 2021 in Investor Center

Imagin Medical Announces Appointment of Kayvon Namvar to Board of Directors and Kevin Slawin, M.D. as Board Chairman

Vancouver, B.C. and Boston, MA, November 8, 2021 – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) “Imagin” or the “Company”), a surgical imaging company visualizing cancer in vital new ways…
Read More
30 August 2021 in Investor Center

Rapha Capital Leads New $3 Million Convertible Note Financing in Imagin Medical, Inc.

Rapha Capital BioVentures Fund I, LP (RCBVFI) managed by Rapha Capital leads the financing. Kevin Slawin, M.D., a leading urooncologist and manager of RCBVFI, joins the board. Imagin Medical's i/Blue™…
Read More
26 August 2021 in Investor Center

IMAGIN MEDICAL Secures New $3 Million Convertible Note Financing

Rapha Capital BioVentures Fund I, LP (RCBVFI), Leads New Convertible Note Financing Kevin Slawin, MD, a Leading UroOncologist and Manager of RCBVFI Joins the Board Imagin Medical’s i/Blue™ Imaging System is…
Read More